Abstract
Purpose: The indispensable role of long non-coding RNAs (lncRNAs) in tumorigenesis has been increasingly reported. In the present study, LINC01694 was found to regulate the proliferation, invasion, as well as apoptosis in gallbladder cancer (GBC) cells through sponging miR-340-5p.Methods: LINC01694 level in GBC cells was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). The proliferation, invasion, and apoptosis were determined by Cell Counting Kit-8 (CCK-8), Transwell, and flow cytometry, respectively. The expression of Sry-related high-mobility group box 4 (Sox4) was detected by Western blot (WB). The interaction between LINC01694 and miR-340-5p was measured by dual-luciferase reporter (DLR) assay, RNA immunoprecipitation (RIP) test, and RNA pull-down. Tumor formation was examined by in vivo experiment.Results: qRT-PCR illustrated that cancerous tissues had higher LINC01694 than normal tissues. Survival analysis demonstrated that the prognosis of patients with high LINC01694 was significantly poorer than those with low LINC01694. Down-regulation of LINC01694 slowed down the proliferation and invasion in GBC cells and accelerated the apoptosis. DLR assay indicated that LINC01694 elevated Sox4 expression by regulating miR-340-5p. LINC01694 functioned as miR-340-5p sponge to inhibit Sox4 expression.Conclusion: LINC01694 level is elevated in GBC by regulating miR-340-5p/Sox4 axis, which indicates the poor prognosis of the patients.
Highlights
Gallbladder cancer (GBC) is a prevalent biliary duct tumor and the sixth most common gastrointestinal cancer in the world [1,2]
We performed quantitative real-time polymerase chain reaction (qRT-PCR) and found that the expression of LINC01694 was remarkably elevated in tissues and sera of patients with GBC (Figure 1B), and the area under the curve (AUC) in diagnosing GBC was 0.871 (Figure 1C)
Cox regression illustrated that LINC01694 was an independent factor in the prognosis of GBC patients (Table 3)
Summary
Gallbladder cancer (GBC) is a prevalent biliary duct tumor and the sixth most common gastrointestinal cancer in the world [1,2]. In a tumor epidemiological survey, more than 150000 each new and dead cases of GBC patients were reported in 2018 [3]. The morbidity and mortality are relatively low compared with other digestive tract tumors, the 5-year survival remains extremely poor. GBC is diagnosed at an advanced stage due to the occult early symptoms and the lack of diagnostic markers [4,5]. Improvements can be made by radiotherapy and chemotherapy, the survival and prognosis of advanced patients is still disappointing. Seeking potential diagnostic and molecular targets for GBC is of great significance [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
